酒糟：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 法國酒糟市場預計將從 2025 年的 4,800 萬美元成長到 2035 年的 9,800 萬美元。
• 推動市場成長的因素如下：
• 診斷數量增加和對該疾病的認知提高
• 擴大標靶局部和全身療法的應用範圍。
• 未來的成長取決於能夠持續控制疾病並改善患者預後的療法。

酒糟概述

酒糟是一種慢性、多因子發炎性皮膚病，表現為持續性臉部發紅、可見的血管、發炎性丘疹或皮膚增厚。由於這些症狀常常相互重疊，患者傳統上必須使用多種局部治療藥物，而這些藥物一次只能針對一種症狀。雖然針對發炎性病變的口服抗生素長期以來一直是系統性治療的基礎，但多年來一直沒有核准的藥物能夠同時解決發炎和血管因素——即導致發紅的因素——這迫使即使是病情控制良好的患者也只能採用零散的治療方法。然而，近年來，隨著新型緩釋口服藥物的出現，這一差距有所縮小，這些藥物已被證實能夠同時改善這兩個方面，有望成為新的標準治療方案，而不僅僅是局部治療鏈中的又一個步驟。對該疾病潛在生物學機制的進一步研究，包括免疫活化、皮膚屏障功能障礙和皮膚微生物群，將繼續為下一代標靶治療的出現提供新的見解。對於相關人員而言，酒糟正逐漸成為一種常見的慢性疾病，其關注點正從無窮無盡的針對特異性症狀的產品清單轉向更全面的系統性療法。

主要亮點

• 根據預測，德國的酒糟診斷數量將從 2025 年的 2,501,746 例增加到 2035 年的 2,819,254 例。
• 酒糟是一種慢性發炎性皮膚病，其特徵是臉部持續性紅斑、潮紅和發炎性病變。
• 這種疾病嚴重影響患者的生活品質，而且經常復發，需要長期治療。
• 目前仍有大量未被滿足的治療需求，即能夠持續控制症狀並防止復發的治療方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• CAGE Bio Inc.
• Tarsus Pharmaceuticals, Inc.

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法－概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興療法實現的潛力。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Rosacea Market Outlook

Thelansis's "Rosacea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Rosacea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Rosacea Overview

Rosacea is a chronic, multifaceted inflammatory skin condition that can present as persistent facial redness, visible blood vessels, inflammatory bumps, or thickened skin, often in overlapping combinations that have historically required patients to combine several topical treatments, each addressing only one symptom at a time. Oral antibiotics targeting inflammatory lesions have long anchored systemic care, but for years no approved therapy addressed both the inflammatory and vascular, redness-driving components together, forcing a fragmented approach even for well-managed patients. That gap narrowed recently with a new extended-release oral therapy shown to improve both dimensions simultaneously, positioning it as a potential new standard rather than another incremental topical option. Deeper research into the disease's underlying biology, including immune activation, skin barrier dysfunction, and the skin microbiome, continues to inform where the next targeted therapies may emerge. For stakeholders, rosacea shows a common, chronic condition still consolidating around more comprehensive systemic solutions rather than an ever-growing list of symptom-specific products.

Key Highlights

• In Germany, diagnosed Rosacea cases are projected to increase from 2,501,746 in 2025 to 2,819,254 by 2035.
• Rosacea is a chronic inflammatory skin disorder characterized by persistent facial erythema, flushing, and inflammatory lesions.
• The disease significantly impacts patients' quality of life, with frequent relapses requiring long-term management.
• Significant unmet need remains for therapies that provide sustained symptom control and reduce disease recurrence.

Market Overview

• The France Rosacea market is projected to grow from $48M in 2025 to $98M by 2035.
• Market growth is driven by:
• Increasing diagnosis and disease awareness
• Growing adoption of targeted topical and systemic therapies
• Future growth will depend on therapies offering durable disease control and improved patient outcomes.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CAGE Bio Inc.
• Tarsus Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)